Louisiana 2017 Regular Session

Louisiana Senate Bill SB59

Introduced
3/28/17  
Introduced
3/28/17  
Refer
3/28/17  
Refer
3/28/17  
Refer
4/10/17  
Refer
4/10/17  
Report Pass
5/3/17  
Engrossed
5/11/17  
Refer
5/15/17  
Refer
5/15/17  
Report Pass
5/23/17  
Report Pass
5/23/17  
Enrolled
6/3/17  
Chaptered
6/14/17  

Caption

Provides relative to prescription drug price information. (gov sig)

Companion Bills

No companion bills found.

Previously Filed As

LA HB436

Requires drug manufacturers to provide information regarding prescription drug prices (EN NO IMPACT See Note)

LA HB616

Provides for disclosure of prescription drug cost information

LA H1183

Prescription Drug Price Transparency

LA H1509

Prescription Drugs

LA S875

To promote transparency in prescription drug prices

LA SB96

Provides relative to the prescription monitoring program. (gov sig) (EN SEE FISC NOTE SG RV)

LA HB1135

Provide for transparency in the pricing of prescription drugs.

LA HB961

Requires educational or marketing materials for prescription drugs directed to healthcare providers to include price information

LA SB282

Provides relative to prescription drug pricing. (8/1/18) (EN NO IMPACT See Note)

LA SB00013

An Act Reducing Prescription Drug Prices.

Similar Bills

LA SB29

Provides relative to a single uniform prescription drug prior authorization form. (See Act) (RE SEE FISC NOTE SG EX See Note)

LA HB548

Requires that the prescribers transmit prescriptions for opioids to pharmacies electronically (EG SEE FISC NOTE SG EX See Note)

LA HB384

Creates and provides for a state prescription drug importation program (OR INCREASE SG EX See Note)

LA HR114

Requests an evaluation by La. officials of efforts to deter prescription drug abuse and recommendations for best practices to combat such abuse

LA HR181

Urges and requests the Louisiana Department of Health to study the desirability and feasibility of adopting state policy to provide for review of prescription drug prices in the medical assistance program

LA SB496

Provides for limits on certain medical prescriptions. (8/1/14)

LA HR156

Authorizes and directs the Louisiana Supreme Court to study extending liberative prescriptive periods to two years and to compile data relative to Louisiana's threshold for a civil jury trial

LA SCR31

Requests the Department of Economic Development and the Department of Revenue to develop an incentive package that will make Louisiana the domestic prescription drug manufacturing leader for the United States.